PT - JOURNAL ARTICLE AU - Whelan, Stephen A. AU - Hendricks, Nathan AU - Dwight, Zachary L. AU - Fu, Qin AU - Moradian, Annie AU - Van Eyk, Jennifer E. AU - Mockus, Susan M. TI - Assessment of a 60-biomarker health surveillance panel (HSP) on whole blood from remote sampling devices by targeted LC/MRM-MS and discovery DIA-MS analysis AID - 10.1101/2023.02.04.23285394 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.04.23285394 4099 - http://medrxiv.org/content/early/2023/02/07/2023.02.04.23285394.short 4100 - http://medrxiv.org/content/early/2023/02/07/2023.02.04.23285394.full AB - Summary Telehealth, accessing healthcare and wellness remotely, should be a cost effective and efficient way for individuals to receive care. The convenience of having a robust remote collection device for blood tests will facilitate access to precision medicine and healthcare. Herein, we tested a 60-biomarker health surveillance panel (HSP), containing 35 FDA/LDT assays and covering at least 14 pathological states, on 8 healthy individuals’ ability to collect their own capillary blood from a lancet finger prick and directly compared to the traditional phlebotomist venous blood and plasma collection methods. Samples were quantitatively analyzed by a liquid chromatography-multiple reaction monitoring-mass spectrometry method targeting 114 peptides representing 60 HSP proteins and by a data-independent acquisition mass spectrometry discovery method, resulting in up to 3,811 protein identifications including 122 FDA approved biomarkers. The >90% similarity between the three biofluids indicate that remote collection devices are a viable option for personal blood proteome biosignature stratification and health analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee Cedars-Sinai Medical Center (CSMC) IRB No: STUDY00000621 / MOD00004460 CSMC Date Effective: 9/23/2021 gave ethical approval for all human samples used in this study. Any potential identifying dates in Supplemental Table S5 have been converted to month and year.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll search results are included in the supplemental excel files. All LC/MRM-MS raw files have been deposited to the PASSEL PeptideAtlas repository with the dataset identifier PASS03796. All DIA-MS raw files and search results have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD038678. http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD038678 http://www.peptideatlas.org/passel/